Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (257)	2/6/1998 11:18:00 AM
From: Paul S.	Respond to of 1185

We are back through the dollars, and it looks pretty thin on the upside, I think this is a pretty good press release(moving into phase two is a big step in the right direction) FJ is it possible to get your comments. Correct me if I'm wrong but dont the fundamentals of this company get better and better every day. Now all we need is a CEO.

To: David Culver who wrote (257)	2/6/1998 11:39:00 AM
From: Paul S.	Read Replies (1) \| Respond to of 1185

thought I'd post the news! Nortran & ACIC In Negotiations For RSD921 Manufacturing Sublicense Nortran Pharmaceuticals Inc. (VSE:NRT, OTCBB:NTRDF) is pleased to announce that ACIC Fine Chemicals Inc., of Mississauga, Canada has reached an agreement in principle and is negotiating the formal terms with the Company for a North American and European manufacturing license and an option on a marketing license for the Company's novel local anesthetic and antiarrhythmic compound,RSD921. Under the terms of the proposed agreement, ACIC, a private company with international bulk pharmaceutical operations, will be responsible for scale-up and GMP (Good Manufacturing Practice) manufacturing of bulk RSD921. Methapharm Inc., an affiliate of ACIC, will carry out formulation, labeling, packaging, and marketing. In advance of the formal agreement, ACIC's European affiliate has begun work scaling up the RSD921 process for the upcoming Phase II clinical trials. ACIC is a major supplier of bulk pharmaceuticals and fine chemicals to international and multinational pharmaceutical companies. Methapharm is a supplier of branded pharmaceuticals with a focus on hospital based products. Nortran is a drug discovery company whose focus is pathology targeted small molecules. Nortran's current drugs in development target the ion channels responsible for life-threatening arrhythmias of the heart and for intractable pain. ON BEHALF OF THE BOARD Allen I. Bain, Ph.D. President